Company / Cost of Revenue
Amgen Cost of Revenue History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$12.0B
FY2025
5-year range
$4.4B / $12.9B
FY2021-FY2025
Trend
-6.4%
vs FY2024
Sector context
#6 of 85
Health Care
What the data says
Among 85 Health Care companies, Amgen is in the bottom 7% for cost of revenue. Increased from $8.5B to $12.0B over the past 2 years.
Based on SEC 10-K filings.
$12.0B in FY2025 with a 5-year CAGR of +24.0%. Top quartile in the Health Care sector.
Increased from $8.5B to $12.0B over the past 2 years.
Health Care sector context is included.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- +25.0%
- 5-Year CAGR
- +24.0%
- 10-Year CAGR
- -
Sector benchmark
Bottom 7% in Health CareTop 93% of 85This company $12.0B Sector average $2.0B
▼
+507.0% above sector average
Key checks
Key Insights
- 5-year CAGR of +24.0%, indicating consistent growth.
- In FY2025, cost of revenue decreased 6.4% year-over-year.
- Ranks #6 out of 85 companies in the Health Care sector.
- Peak cost of revenue was recorded in FY2024.
Company context
Key Data Points
- Altman Z-Score 0.55 (distress zone, below 1.8 threshold)
- Strong return on equity: 72.8%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $12.0B | -6.4% |
| FY2024 | $12.9B | +52.1% |
| FY2023 | $8.5B | +37.2% |
| FY2022 | $6.2B | +41.4% |
| FY2021 | $4.4B | +6.2% |
| FY2020 | $4.1B | +0.8% |
| FY2019 | $4.1B | -2.2% |
| FY2018 | $4.2B | -1.5% |
| FY2017 | $4.2B | -4.4% |
| FY2016 | $4.4B | +4.6% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026